Published in Eur J Clin Pharmacol on September 16, 2012
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer (2014) 0.90
Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer. BMC Cancer (2013) 0.79
Development and Validation of an Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Method for Quantitative Analysis of Platinum in Plasma, Urine, and Tissues. Appl Spectrosc (2016) 0.75
Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells. Am J Cancer Res (2016) 0.75
Peritonectomy procedures. Ann Surg (1995) 4.24
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol (2011) 4.16
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol (2011) 2.35
Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol (2008) 1.56
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol (2002) 1.55
In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res (1980) 1.19
Role of ligand exchange processes in the reaction kinetics of the antitumor drug cis-diamminedichloroplatinum(II) with its targets. Cancer Res (1985) 1.06
Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J (2009) 1.04
Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci (1996) 0.96
Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs (2005) 0.90
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol (1999) 0.89
The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol (1991) 0.84
Population pharmacokinetics with a very small sample size. Drug Metabol Drug Interact (2009) 0.83
Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. J Clin Pharmacol (2010) 0.83
Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol (2009) 0.83
Preparation and metabolism of a cisplatin/serum protein complex. Chem Biol Interact (1980) 0.83
In vitro cytokinetic response of human colon cancer cells to cis-dichlorodiammineplatinum(II). Cancer Res (1979) 0.82
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol (2007) 0.81
Time- and concentration-dependent inhibition of the clonogenic growth of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced murine bladder tumor cell lines by cis-diamminedichloroplatinum(II). Cancer Res (1982) 0.79
Quantitative liquid chromatographic determination of intact cisplatin in blood with microwave-assisted post-column derivatization and UV detection. J Pharm Biomed Anal (2011) 0.78
Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis. Cancer Treat Res (1996) 0.78
Stability of cisplatin and its monohydrated complex in blood, plasma and ultrafiltrate--implications for quantitative analysis. J Pharm Biomed Anal (1995) 0.77
Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. J Chromatogr (1994) 0.76
The kinetics and cytotoxicity of cisplatin and its monohydrated complex. Cancer Lett (1998) 0.76
Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol (1988) 0.76
Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies. Ann Oncol (1991) 0.75
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity. Anticancer Res (2003) 0.75
Analytical methodologies for the quantitation of platinum anti-cancer drugs and related compounds in biological media. J Pharm Biomed Anal (1990) 0.75
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol (2006) 2.13
Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A (1999) 1.91
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol (2009) 1.77
A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol (2001) 1.61
Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol (2012) 1.58
Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol (2008) 1.56
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol (2004) 1.51
A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol (2001) 1.46
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer (1992) 1.37
A systematic overview of chemotherapy effects in breast cancer. Acta Oncol (2001) 1.36
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol (2011) 1.33
Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg (2012) 1.31
Determination of sulphonamides by electron-capture gas chromatography. Preparation and properties of perfluoroacyl and pentafluorobenzyl derivatives. J Chromatogr (1975) 1.25
Analysis of oligonucleotide probe affinities using surface plasmon resonance: a means for mutational scanning. Anal Biochem (1997) 1.24
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer (2004) 1.17
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer (2003) 1.16
Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials. Eur J Cancer Care (Engl) (2014) 1.11
Risk factors for cardiovascular disease during the period 1985-1995 in Göteborg, Sweden. The GOT-MONICA Project. J Intern Med (1997) 1.07
Dynamics of nonstructural carbohydrates and biomass yield in a fodder legume tree at different harvest intensities. Tree Physiol (2001) 1.07
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 1.05
Pharmacokinetics of oxaliplatin in humans. Med Oncol (2002) 1.04
Cisplatin-induced hearing loss: influence of the mode of drug administration in the guinea pig. Hear Res (2000) 1.04
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer (1996) 1.03
A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol (2001) 1.02
Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos (1999) 1.02
An expanded CAG repeat sequence in spinocerebellar ataxia type 7. Genome Res (1996) 1.02
Assessment of quality of life during chemotherapy. Acta Oncol (2001) 0.99
Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng (1999) 0.99
A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol (2001) 0.99
Management of menopause-related symptoms. Evid Rep Technol Assess (Summ) (2005) 0.98
Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol (1989) 0.98
Determination of 8-methoxypsoralen in plasma by electron capture gas chromatography. J Chromatogr (1977) 0.97
Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci (1996) 0.96
Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol (2007) 0.95
A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol (2008) 0.94
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol (2006) 0.94
Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031). Eur J Clin Pharmacol (1983) 0.93
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia (2000) 0.93
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs (1992) 0.93
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol (1995) 0.92
Busulfan bioavailability. Blood (1994) 0.92
Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. Ann Oncol (2011) 0.90
Serum concentration and phototoxic effect of methoxsalen in patients with psoriasis. Clin Pharmacol Ther (1979) 0.90
Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol (2011) 0.90
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol (1994) 0.90
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Eur J Cancer (1996) 0.89
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer (1999) 0.89
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol (1998) 0.89
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol (1991) 0.89
Quantitative determination of melphalan in plasma by liquid chromatography after derivatization with N-acetylcysteine. J Chromatogr (1986) 0.89
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. Biochem Pharmacol (2001) 0.89
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer (1994) 0.89
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol (1993) 0.89
A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res (1989) 0.89
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol (2005) 0.89
Vaginal birth after cesarean (VBAC). Evid Rep Technol Assess (Summ) (2003) 0.87
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs (1994) 0.87
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol (1996) 0.87
Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma (1996) 0.86
Alkaline single-cell gel electrophoresis and human biomonitoring for genotoxicity: a pilot study on breast cancer patients undergoing chemotherapy including cyclophosphamide. Mutat Res (1997) 0.86
Stability towards alkaline conditions can be engineered into a protein ligand. J Biotechnol (2000) 0.86
Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res (2007) 0.86
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer (1997) 0.85
EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep (2011) 0.85
A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol (2001) 0.85
In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol (1992) 0.85
Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol (2008) 0.85
Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant (1989) 0.84
Busulfan kinetics. Clin Pharmacol Ther (1983) 0.84
Calcium-activated calcium permeability in parathyroid cells. FEBS Lett (1986) 0.84
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer (1997) 0.84
Quantitative investigation of the modular primer effect for DNA and peptide nucleic acid hexamers. Anal Biochem (1999) 0.84
Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol (2005) 0.84
Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB. Biochem Pharmacol (2000) 0.84
Intracochlear administration of thiourea protects against cisplatin-induced outer hair cell loss in the guinea pig. Hear Res (2003) 0.84
Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei. Eur J Surg Oncol (2012) 0.83
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer (2000) 0.83
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours. Eur J Cancer (1994) 0.83
Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother Pharmacol (1995) 0.83
Quantitative gas chromatographic determination of carboxylic acids and phenols after derivatization with pentafluorobenzyl bromide. Evaluation of reaction conditions. Acta Pharm Suec (1971) 0.82
Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. J Chromatogr (1979) 0.82
Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. Eur J Pharmacol (2001) 0.82
A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol (2001) 0.82
Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia (1990) 0.82
Binding of busulfan to plasma proteins and blood cells. J Pharm Pharmacol (1984) 0.81
Degradation of chlorambucil in aqueous solution--influences of human albumin binding. J Pharm Pharmacol (1981) 0.81